Insights

GraftAssure Launch Position for early SDR outreach around GraftAssureDx readiness and upcoming FDA regulatory status, highlighting opportunities to engage transplant centers and nephrology departments preparing for post-approval adoption.

Transplant Focus Leverage the growing interest in dd-cfDNA testing for organ rejection monitoring by targeting transplant programs and hospital systems expanding their precision diagnostics capabilities, including kidney and heart transplantation.

Clinical Validation Emphasize CLIA-certified and CAP-accredited labs to build trust with hospital procurement and payers, underscoring reliability and regulatory compliance as a differentiator in selling advanced molecular diagnostics.

Strategic Outreach Tap into investor and industry events (BIG10 conference, virtual KOL events) to generate top-of-funnel interest, engaging KOLs, biomedical researchers, and hospital decision-makers for pilot programs.

Medicare Reimbursement Highlight recent Lancet Regional Health publication supporting dd-cfDNA monitoring and confirmed Medicare reimbursement coverage to address payer concerns and catalyze reimbursement-ready pilot studies.

Similar companies to iMDx

iMDx Tech Stack

iMDx uses 8 technology products and services including HubSpot Analytics, Linkedin Insight Tag, GitHub, and more. Explore iMDx's tech stack below.

Media & News

iMDx's Email Address Formats

iMDx uses at least 5 email formats:
iMDx Email FormatsExamplePercentage
FLast@oncocyte.comJDoe@oncocyte.com
90%
First.Last@oncocyte.comJohn.Doe@oncocyte.com
6%
LastFirst@oncocyte.comDoeJohn@oncocyte.com
3%
LastFi@oncocyte.comDoeJo@oncocyte.com
1%
FLast@imdxinc.comJDoe@imdxinc.com
100%

Frequently Asked Questions

What is iMDx's phone number?

Minus sign iconPlus sign icon
You can contact iMDx's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is iMDx's stock symbol?

Minus sign iconPlus sign icon
iMDx is a publicly traded company; the company's stock symbol is IMDX.

What is iMDx's official website and social media links?

Minus sign iconPlus sign icon
iMDx's official website is imdxinc.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does iMDx generate?

Minus sign iconPlus sign icon
As of October 2026, iMDx's annual revenue is estimated to be $1M - $10M.

What is iMDx's SIC code and NAICS code?

Minus sign iconPlus sign icon
iMDx's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does iMDx have currently?

Minus sign iconPlus sign icon
As of October 2026, iMDx has approximately 73 employees across 2 continents, including North America and Europe. Key team members include President & Chief Operating Officer: G. P., Interim Chief Executive Officer: J. R. and Director Of Business Development: D. B. Explore iMDx's employee directory with LeadIQ.

What industry does iMDx belong to?

Minus sign iconPlus sign icon
iMDx operates in the Biotechnology Research industry.

What technology does iMDx use?

Minus sign iconPlus sign icon
iMDx's tech stack includes HubSpot Analytics, Linkedin Insight Tag, GitHub, Kubernetes, OpenAI, DocuSign, Microsoft Azure and Smartsheet.

What is iMDx's email format?

Minus sign iconPlus sign icon
iMDx's email format typically follows the pattern of FLast@oncocyte.com. Find more iMDx email formats with LeadIQ.

How much funding has iMDx raised to date?

Minus sign iconPlus sign icon
As of October 2026, iMDx has raised $138M in funding. The last funding round occurred on Feb 11, 2026 for $29M.
iMDx logo

iMDx

Biotechnology ResearchTennessee, United States51-200 Employees

iMDx is a biotechnology company based in Nashville, Tennessee, focused on precision diagnostics for oncology and transplantation. It operates CLIA-certified and CAP-accredited laboratories and aims to deliver accurate, clinically meaningful molecular diagnostic results while expanding access to advanced diagnostics to support early detection and personalized treatment. The company employs between 51 and 200 people. Its flagship GraftAssure transplant rejection monitoring assay has been the subject of recent press coverage and peer-reviewed publications, with reports of improved screening performance for kidney transplant patients and progress toward commercialization. iMDx engages with the transplant community through conference presentations and collaborations with transplant centers to advance its transplant testing program.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
IMDX
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
51-200

Section iconFunding & Financials

  • $138M

    iMDx has raised a total of $138M of funding over 8 rounds. Their latest funding round was raised on Feb 11, 2026 in the amount of $29M as a Post IPO Equity.

  • $1M - $10M

    iMDx's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.